Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | SQLE | Q14534 | 7/20 | 0.50 |
| ▸ | FNTA | P49354 | 2/20 | 0.48 |
| ▸ | FNTB | P49356 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23458529 | 1.00 | KMT2A (0.52) | KMT2ASQLEFNTAFNTBMAPT | |
| SCHEMBL8940810 | 0.86 | KMT2A (0.64) | KMT2ASQLEFNTAFNTBMAPT | |
| SCHEMBL1105232 | 0.86 | KMT2A (0.64) | KMT2ASQLEFNTAFNTBMAPT | |
| SCHEMBL4307163 | 0.84 | KMT2A (0.60) | KMT2ASQLEMAPTMEN1CYP3A4 | |
| SCHEMBL806716 | 0.84 | KMT2A (0.60) | KMT2ASQLEMAPTMEN1CYP3A4 | |
| SCHEMBL28814759 | 0.80 | KMT2A (0.45) | KMT2ASQLEFNTAFNTBMAPT | |
| SCHEMBL14825999 | 0.79 | KMT2A (0.70) | KMT2ASQLEFNTAFNTBMAPT | |
| SCHEMBL9474305 | 0.79 | KMT2A (0.70) | KMT2ASQLEFNTAFNTBMAPT | |
| SCHEMBL9474308 | 0.79 | KMT2A (0.70) | KMT2ASQLEFNTAFNTBMAPT | |
| SCHEMBL9474310 | 0.79 | KMT2A (0.70) | KMT2ASQLEFNTAFNTBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11965195-B2 | Enzyme mediated process | GIVAUDAN SA (CH) | 2024-04-23 | — | — | US | disclosed |
| US-20230009254-A1 | ENZYME MEDIATED PROCESS | GIVAUDAN SA (CH) | 2023-01-12 | — | — | US | disclosed |
| EP-4069858-A1 | ENZYME MEDIATED PROCESS | Givaudan SA (CH) | 2022-10-12 | — | — | EP | disclosed |
| WO-2021110858-A1 | ENZYME MEDIATED PROCESS | GIVAUDAN SA (CH) | 2021-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11965195-B2 | Enzyme mediated process | HPD, DNPH1, ESD | KMT2A 1439/4885SQLE 183/4885FNTA 1187/4885 |
| US-20230009254-A1 | ENZYME MEDIATED PROCESS | HPD, DNPH1, ESD | KMT2A 1439/4885SQLE 183/4885FNTA 1187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.